Literature DB >> 28885273

A Comparative Study of Video Endoscopic Inguinal Lymphadenectomy and Conventional Open Inguinal Lymphadenectomy for Treating Vulvar Cancer.

Menglei Zhang1, Limei Chen, Xuyin Zhang, Jingxin Ding, Keqin Hua.   

Abstract

OBJECTIVE: This study aims to compare the complications, oncological outcomes, cosmetic satisfaction, and quality of life experienced by women with vulvar cancer undergoing video endoscopic inguinal lymphadenectomy (VEIL) versus conventional open inguinal lymphadenectomy (COIL). PATIENTS AND METHODS: Forty-eight consecutive patients with vulvar cancer who underwent COIL (n = 27) or VEIL (n = 21) at the Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China between 2003 and 2016 were included in this retrospective cohort study. The perioperative data, postoperative complications, oncological outcomes, cosmetic satisfaction, and quality of life of the COIL and VEIL groups were compared.
RESULTS: Twenty patients (74.1%) in the COIL group and 19 patients (90.5%) in the VEIL group returned for follow-up after the operation. The median follow-up time was 73 months (8-162 months) for the COIL group and 28 months (8-58 months) for the VEIL group. The inguinal lymph node yield in the VEIL group was comparable with that in the COIL group (15 ± 5 vs 18 ± 6, P = 0.058). The VEIL and COIL groups had a similar 2-year recurrence rate (10.5% vs 10%, P = 0.957) and 2-year disease-specific survival rate (95.5% vs 93.3%, P = 0.724). The wound complication rate was significantly lower in the VEIL group than the COIL group (4.8% vs 55.6%, P = 0.000). The VEIL group had higher body image scores (16.27 ± 1.20 vs 13.16 ± 0.87, P < 0.0001) and cosmetic scores (20.13 ± 0.98 vs 16.92 ± 0.72, P < 0.0001) than the COIL group. The patients in the VEIL group had higher life quality scores on the Functional Assessment of Cancer Therapy-Vulvar questionnaire than those in the COIL group (165.9 ± 6.3 vs 160.5 ± 6.0, P = 0.026).
CONCLUSIONS: Compared with COIL, VEIL can effectively reduce postoperative wound complications and improve patients' cosmetic satisfaction and life quality without compromising therapeutic efficacy. Hence, we believe that VEIL is a good alternative to COIL for vulvar cancer patients when surgical expertise is available.

Entities:  

Mesh:

Year:  2017        PMID: 28885273     DOI: 10.1097/IGC.0000000000001100

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

1.  Safety and feasibility of single-incision radical vulvectomy: a novel approach for the treatment of vulvar cancer.

Authors:  Liqing He; Gaowen Chen; Xiaoxuan Li; Youhong Zheng; Mengting Wu; Huiyan Wang; Xiaohong Liu; Wuqi He; Xiaodan Liu; Shaozhuo Huang; Fan Lin; Weixin Liao; Ying Ma; Yifeng Wang
Journal:  Ann Transl Med       Date:  2021-02

2.  VEILND (Video Endoscopic Inguinal Lymph Node Dissection) with Florescence Indocyanine Green (ICG): A Novel Technique to Identify the Sentinel Lymph Node in Men with ≥pT1G2 and cN0 Penile Cancer.

Authors:  Milan Hora; Ivan Trávníček; Štěpánka Nykodýmová; Jiří Ferda; Denisa Kacerovská; Květoslava Michalová; Ondřej Hes; Suks Minhas
Journal:  Contrast Media Mol Imaging       Date:  2021-10-29       Impact factor: 3.161

3.  A single-center comparison of our initial experiences in treating penile and urethral cancer with video-endoscopic inguinal lymphadenectomy (VEIL) and later experiences in melanoma cases.

Authors:  A Gómez-Ferrer; A Collado; M Ramírez; J Domínguez; J Casanova; C Mir; A Wong; J L Marenco; E Nagore; V Soriano; J Rubio-Briones
Journal:  Front Surg       Date:  2022-09-26

4.  Comparison of two types of the triple incision technique in the treatment of patients with locally advanced vulvar cancer.

Authors:  Ying Ma; Wei-Feng Liang; Chang-Hao Liu; Zhong-Qiu Lin; Miao-Fang Wu; Jing Li
Journal:  Int J Med Sci       Date:  2020-09-16       Impact factor: 3.738

5.  Comparison of the two routes of video endoscopic inguinal lymphadenectomy in vulvar cancer: a systematic review and a single-center experience.

Authors:  Lixia Luan; Rui Chen; Yang Yang; Fangfang Xue; Wenying Wang
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.